12/13/25 - S12 E 600: DR. SHOSHANA SHENDELMAN – BIOTECH’S INNOVATION PARADOX

12/13/25 - S12 E 600: DR. SHOSHANA SHENDELMAN – BIOTECH’S INNOVATION PARADOX

What drives biotech companies to prioritise cosmetics over life-saving cures? In this thought-provoking episode, Dr. Shoshana Shendelman, a seasoned scientist and entrepreneur, shares her insights on the current trends in the biotech industry. The conversation delves into the economic and regulatory factors that steer companies towards the more lucrative and less risky cosmetic market. As Dr. Shendelman explains, the FDA's unpredictable nature and the high costs of drug development make it challenging for companies to invest in groundbreaking medical cures.

Dr. Shendelman highlights the stark reality of drug approval processes, where less than 10% of drugs make it through to the market. This episode explores the complexities of balancing profit with the moral obligation to cure diseases. With light humour, the hosts and Dr. Shendelman discuss potential solutions, such as holding the FDA accountable for their guidance and incentivising drug development for underserved diseases.

Listeners will gain a deeper understanding of why cosmetic products are becoming more prevalent and how this shift impacts patients in need of life-saving treatments. This episode is a must-listen for anyone curious about the inner workings of the biotech industry and the ethical dilemmas faced by pharmaceutical companies. Could there be a way to encourage more innovation in life-saving treatments? Tune in to find out.